U
15.69
-0.72 (-4.39%)
| Penutupan Terdahulu | 16.41 |
| Jumlah Dagangan | 1,005,518 |
| Harga / Jualan (P/S) | 2.14 |
| Julat 52 Minggu |
| Margin Keuntungan | -93.04% |
| Margin Operasi (TTM) | -102.62% |
| EPS Cair (TTM) | -5.83 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 588.24% |
| Nisbah Semasa (MRQ) | 2.40 |
| Aliran Tunai Operasi (OCF TTM) | -389.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -172.94 M |
| Pulangan Atas Aset (ROA TTM) | -24.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -377.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ultragenyx Pharmaceutical Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Nilai 35% | -2.6 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -2.6 |
| Masa 35% | 1.7 |
| AI Technical info | NA |
| Osilator Teknikal info | 0.5 |
| Purata Bergerak Teknikal info | 3.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.5% |
| Persetujuan Tonggak | ×0.85 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 1.5 |
| Skor Akhir | -0.33 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.20% |
| % Dimiliki oleh Institusi | 99.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sands Capital Management, Llc | 30 Jun 2026 | 3,158,368 |
| Sofinnova Investments, Inc. | 30 Jun 2026 | 1,717,505 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |